ANI Pharmaceuticals, Inc. (ANIP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.94% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
- ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
- Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
- ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
- Implied Volatility Surging for ANI Pharmaceuticals Stock Options
- Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
- ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
- ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for ANI Pharmaceuticals, Inc..
Full ANIP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.